131 related articles for article (PubMed ID: 14592998)
21. Antithrombin and its deficiency states.
Lane DA; Olds RR; Thein SL
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):315-41. PubMed ID: 1643210
[TBL] [Abstract][Full Text] [Related]
22. Molecular basis of inherited antithrombin deficiency in Portuguese families: identification of genetic alterations and screening for additional thrombotic risk factors.
David D; Ribeiro S; Ferrão L; Gago T; Crespo F
Am J Hematol; 2004 Jun; 76(2):163-71. PubMed ID: 15164384
[TBL] [Abstract][Full Text] [Related]
23. Identification of two de novo mutations responsible for type I antithrombin deficiency.
Orlando C; Lissens W; Hasaerts D; Jochmans K
Thromb Haemost; 2012 Jan; 107(1):187-9. PubMed ID: 22116592
[No Abstract] [Full Text] [Related]
24. [Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
Sakuragawa N; Niiya K; Takahashi K; Hayashi T; Oguma Y; Saitoh S
Rinsho Byori; 1993 May; 41(5):492-505. PubMed ID: 8350512
[TBL] [Abstract][Full Text] [Related]
25. Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy.
O'Ddonnell JS; Hinkson L; McCarthy A; Manning R; Khan A; Laffan MA
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):217-20. PubMed ID: 16575261
[TBL] [Abstract][Full Text] [Related]
26. Two new antithrombin variants support a role for K114 and R13 in heparin binding.
Picard V; Susen S; Bellucci S; Aiach M; Alhenc-Gelas M
J Thromb Haemost; 2003 Feb; 1(2):386-7. PubMed ID: 12871518
[No Abstract] [Full Text] [Related]
27. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism.
Martínez-Martínez I; Navarro-Fernández J; Østergaard A; Gutiérrez-Gallego R; Padilla J; Bohdan N; Miñano A; Pascual C; Martínez C; de la Morena-Barrio ME; Aguila S; Pedersen S; Kristensen SR; Vicente V; Corral J
Blood; 2012 Jul; 120(4):900-4. PubMed ID: 22498748
[TBL] [Abstract][Full Text] [Related]
28. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation.
Beauchamp NJ; Pike RN; Daly M; Butler L; Makris M; Dafforn TR; Zhou A; Fitton HL; Preston FE; Peake IR; Carrell RW
Blood; 1998 Oct; 92(8):2696-706. PubMed ID: 9763552
[TBL] [Abstract][Full Text] [Related]
29. [A heterozygous point mutation G13328A in antithrombin gene causes thrombosis].
Zhou RF; Shi GC; Fu QH; Wang WB; Xie S; Dai J; Ding QL; Hu YQ; Wang XF; Deng WW; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):661-4. PubMed ID: 16620552
[TBL] [Abstract][Full Text] [Related]
30. Antithrombins Southport (Leu 99 to Val) and Vienna (Gln 118 to Pro): two novel antithrombin variants with abnormal heparin binding.
Chowdhury V; Mille B; Olds RJ; Lane DA; Watton J; Barrowcliffe TW; Pabinger I; Woodcock BE; Thein SL
Br J Haematol; 1995 Mar; 89(3):602-9. PubMed ID: 7734360
[TBL] [Abstract][Full Text] [Related]
31. Increased venous versus arterial thrombosis in the Factor V Leiden mouse.
Cooley BC; Chen CY; Schmeling G
Thromb Res; 2007; 119(6):747-51. PubMed ID: 16793123
[TBL] [Abstract][Full Text] [Related]
32. Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method.
Corral J; Rivera J; Martínez C; González-Conejero R; Miñano A; Vicente V
J Lab Clin Med; 2003 Nov; 142(5):298-305. PubMed ID: 14647033
[TBL] [Abstract][Full Text] [Related]
33. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice.
Nagai N; Lijnen HR; Cleuren AC; Rosendaal FR; Van Hoef B; Hoylaerts MF; Van Vlijmen BJ
Thromb Haemost; 2007 Oct; 98(4):858-63. PubMed ID: 17938812
[TBL] [Abstract][Full Text] [Related]
34. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
35. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
36. Identification of four new PITX2 gene mutations in patients with Axenfeld-Rieger syndrome.
Vieira V; David G; Roche O; de la Houssaye G; Boutboul S; Arbogast L; Kobetz A; Orssaud C; Camand O; Schorderet DF; Munier F; Rossi A; Delezoide AL; Marsac C; Ricquier D; Dufier JL; Menasche M; Abitbol M
Mol Vis; 2006 Dec; 12():1448-60. PubMed ID: 17167399
[TBL] [Abstract][Full Text] [Related]
37. Thrombosis as a conformational disease.
Corral J; Vicente V; Carrell RW
Haematologica; 2005 Feb; 90(2):238-46. PubMed ID: 15710578
[TBL] [Abstract][Full Text] [Related]
38. Hyperglycaemia impairs antithrombin secretion: possible contribution to the thrombotic risk of diabetes.
Hernández-Espinosa D; Ordóñez A; Miñano A; Martínez-Martínez I; Vicente V; Corral J
Thromb Res; 2009 Sep; 124(4):483-9. PubMed ID: 19573895
[TBL] [Abstract][Full Text] [Related]
39. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins.
Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC
FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911
[TBL] [Abstract][Full Text] [Related]
40. Familial antithrombin III deficiency.
Br Med J; 1978 Feb; 1(6111):508. PubMed ID: 626859
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
